BIO 2015 Dispatches: Can Expanding FDA's 'Breakthrough' Program Be An Answer To High Drug Costs?
This article was originally published in The Pink Sheet Daily
America's Health Insurance Plans interim CEO Dan Durham says taking an indication-based approach, rather than the current product-specific approach, to awarding the designation would allow later-in-class products to reach market more quickly and help drive down the high cost of novel treatments approved under the expedited pathway.
You may also be interested in...
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.